Amarin (AMRN) vs Zentalis Pharmaceuticals (ZNTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Zentalis Pharmaceuticals (ZNTL) has outperformed Amarin (AMRN) over the past year, gaining 45.9% versus a loss of 36.9%. Over five years, AMRN leads with a -88.4% price change compared with -96.5% for ZNTL. Zentalis Pharmaceuticals is the larger company by market cap ($259.0 million vs $254.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRN | ZNTL |
|---|---|---|
| Share price | $12.03 | $2.64 |
| Market cap | $254.11M | $259.04M |
| 1-day change | +0.33% | +5.18% |
| YTD return | -13.83% | +95.56% |
| 1-year return | -36.92% | +45.86% |
| 5-year return | -88.38% | -96.48% |
| Forward P/E | 12.28 | — |
| EPS (TTM) | $-1.20 | $-1.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.90 | $6.95 |
| 52-week low | $11.83 | $1.21 |
| Distance from 52-week high | -42.44% | -62.01% |
| Analyst consensus | none | buy |
| Avg. price target upside | +3.91% | +177.65% |
| Average volume | 66.10K | 1.21M |
| Shares outstanding | 21.12M | 98.12M |
| Employees | 80 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZNTL has outperformed AMRN by 82.8 percentage points over the past year.
About Amarin
AMRN stock →Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees
About Zentalis Pharmaceuticals
ZNTL stock →Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
AMRN vs ZNTL FAQ
Which is bigger, Amarin or Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals (ZNTL) is larger, with a market capitalization of $259.04M compared with $254.11M for Amarin (AMRN).
Which stock has performed better over the past year, AMRN or ZNTL?
ZNTL returned +45.86% over the past 12 months, compared with -36.92% for AMRN (price return, excluding dividends). Past performance does not predict future results.
Are Amarin and Zentalis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.